The new Clinical Practice Guidelines of Cardio-Oncology were released in August 2022. RESILIENCE is proud to count with two relevant members of the Task Force as project investigators. Teresa López-Fernández is the Chairperson of this Clinical Practice Guideline and co-Principal investigator of European Society of Cardiology (ESC) in RESILIENCE project. Raúl Córdoba is the Principal Investigator (PI) of IISD-FJD for RESILIENCE project and was the haematologist participating in the document.
The 2022 European Society of Cardiology Guidelines of Cardio-Oncology is a collaborative project with the participation of the European Hematology Association (EHA). Patients with haematological malignancies suffer from many cardiovascular adverse events and they need the specialized health care provided by a cardiologist with expertise in cardio-oncology. The key points of these guidelines to be followed by haematologists are:
- The document provides standard definitions for cancer therapy–related cardiotoxicity, guidance on baseline risk assessment, and protocols for surveillance of cardiotoxicity during and after cancer treatment.
- Cardio-oncology providers must have a broad knowledge of cardiology, oncology and hematology, with interdisciplinary communication in a multidisciplinary approach to care.
- A guiding principle of the practice of cardio-oncology is to minimize unnecessary cancer therapy interruptions, with the decision to do so based on multidisciplinary discussions.
- Echocardiography and blood-based cardiac biomarkers are the recommended methods used in the assessment and monitoring of cardiotoxicity.
